{"id":"NCT03131648","sponsor":"LEO Pharma","briefTitle":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-30","primaryCompletion":"2018-08-07","completion":"2019-10-10","firstPosted":"2017-04-27","resultsPosted":"2020-11-20","lastUpdate":"2025-03-11"},"enrollment":802,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Initial treatment period - Tralokinumab Q2W","type":"EXPERIMENTAL"},{"label":"Initial treatment period - Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance treatment period - Tralokinumab Q2W","type":"EXPERIMENTAL"},{"label":"Maintenance treatment period - Tralokinumab Q4W","type":"EXPERIMENTAL"},{"label":"Maintenance treatment period - Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance treatment period - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-label treatment - Tralokinumab + optional TCS","type":"EXPERIMENTAL"},{"label":"Open-label short-term- Tralokinumab + optional TCS","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\nTo evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo.\n\nMaintenance objective:\n\nTo evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.","primaryOutcome":{"measure":"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Tralokinumab 300 mg Q2W","deltaMin":95,"sd":null},{"arm":"Placebo Q2W","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":123,"countries":["United States","France","Germany","Japan","Spain"]},"refs":{"pmids":["40879371","40555305","40085349","38563683","37804473","37682422","36473633","36152216","33000465"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":602},"commonTop":["Dermatitis atopic","Viral upper respiratory tract infection","Conjunctivitis","Headache","Pruritus"]}}